For illustrative purposes only.

Prevention With a Purpose

People may benefit from having a variety of HIV prevention options that best fit into their life. HIV has affected certain populations disproportionally. Representation of those communities in HIV clinical trials is important. We are committed to help end the HIV epidemic. The PURPOSE trials will evaluate the safety and efficacy of an investigational, twice-yearly injectable medicine, lenacapavir, to reduce the chance of getting HIV—also known as pre-exposure prophylaxis (PrEP).

For more information on lenacapavir in clinical trials, please click here.

For illustrative purposes only.

PrEP Studies Overview

About PURPOSE 1

Phase 3 study of an investigational drug, lenacapavir, for PrEP and emtricitabine/tenofovir alafenamide (F/TAF) for PrEP in Adolescent Girls and Young Women
This study will be conducted in South Africa and Uganda

Visit PURPOSE 1

About PURPOSE 2

Phase 3 study of an investigational drug, lenacapavir, for PrEP for Cisgender Men, Transgender Women, Transgender Men, and Gender Non-Binary individuals Who Have Sex With Partners Assigned Male at Birth
This study will be conducted in the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand

Visit PURPOSE 2

PURPOSE study investigators, please click here.

For illustrative purposes only.

Looking Forward

We have come a long way in the fight against HIV. The development of drugs to prevent and treat HIV has changed the course of the epidemic. But our work is not done.

For illustrative purposes only.

Lenacapavir Is an Investigational Product

Its safety and efficacy have not been established and it has not been approved for HIV prevention by any regulatory authority. The safety and efficacy of F/TAF for PrEP in cisgender women has not been established and it is not approved for reducing the chance of getting HIV through vaginal sex.

For illustrative purposes only.

Curious About PURPOSE 1?

PURPOSE 1, which will enroll cisgender women, will evaluate an investigational drug, lenacapavir, and an FDA-approved PrEP drug, emtricitabine/tenofovir alafenamide, also known as F/TAF or DESCOVY^®, for PrEP. This trial is taking place in South Africa and Uganda and further information will be available to potential participants in those countries at a later date.

Learn more about PURPOSE 1

For illustrative purposes only.

Want to Know More About PURPOSE 2?

PURPOSE 2 will evaluate an investigational drug, lenacapavir, and will enroll cisgender men, transgender women, transgender men, and gender non-binary individuals who have sex with partners assigned male at birth. This trial is taking place in the United States, South Africa, Peru, Brazil, Argentina, Mexico, and Thailand.

Learn more about PURPOSE 2

Our Goal? Community Inclusion.

Bringing the trial study sites to where the need is the greatest

View a video from Moupali Das, MD, MPH, the Executive Director of HIV Clinical Research at Gilead, as she describes why it was important that PURPOSE 2 add study sites in new locations in the United States.

Video length: 1 min.

Inclusion from the start

Learn about how we think "Having everyone at the table makes the science better."

Video length: 1 min.

Bringing the trial study sites to where the need is the greatest
View a video from Moupali Das, MD, MPH, the Executive Director of HIV Clinical Research at Gilead, as she describes why it was important that PURPOSE 2 add study sites in new locations in the United States.
Video length: 1 min.
Inclusion from the start
Learn about how we think "Having everyone at the table makes the science better."
Video length: 1 min.

Meet Our Community Advisors

The commitment Gilead has to inclusion is reflected in the widely diverse and accomplished individuals who have served as community advisors. Learn more about the people who contributed to the shaping of the PURPOSE study protocols.

PURPOSE 1: Yvette Raphael
PURPOSE 2: Jenna Rapues